CAR-T Survival Outcomes Unrelated to Household Poverty and Neighborhood Opportunity in ALL
Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.
Diagnosis & Disease Information
Texas-Mexico Border Residence Linked to Worse Survival in Children With ALL
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.
Tecartus Approved for Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL.
CAR-T Therapy in Pediatric Leukemia: Past, Present, and Future
Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.
FDA Approves Additional Dosing Schedule for Rylaze
The MWF dosing option was approved under the Real-Time Oncology Review program based on data from the intramuscular administration part of a phase 2/3 trial.
Nonresponse to Tisagenlecleucel Associated With Poor OS in B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether a lack of response to tisagenlecleucel had a link with survival in patients with B-ALL.
Real-World Data Suggest Tisagenlecleucel Is Effective in Infant B-ALL
Researchers sought to determine whether tisagenlecleucel was effective would be effective in infant patients with B-ALL
Illegitimate Online Pharmacies May Put Cancer Patients at Risk
Illegitimate online pharmacies are selling imatinib without a prescription, making false claims about being registered with regulatory bodies, and failing to provide patients with drug-related warnings.
BMP4 Expression Levels May Predict Clinical Outcomes in Pediatric BCP-ALL
Researchers sought to determine whether BMP4 levels would be predictive of outcomes in pediatric patients with B cell precursor acute lymphoblastic leukemia.
Blinatumomab Linked to Higher Costs, Hospitalizations for R/R ALL
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...